Rivka Bortz
Family · Baltimore, MDNPI 1437708286
Payments from drug & device makers
Across 145 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$581
- Lilly USA, LLC$484
- AstraZeneca$372
- Boehringer Ingelheim$289
- AbbVie$205
- Pfizer$145
- plus $700 from 16 others
What the payments were for
- Food & beverage$2,75899%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $581 |
| Lilly USA, LLC | 26 | $484 |
| AstraZeneca | 24 | $372 |
| Boehringer Ingelheim | 13 | $289 |
| AbbVie | 6 | $205 |
| Pfizer | 7 | $145 |
| Merck | 6 | $132 |
| GSK | 7 | $128 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Eisai Inc. | 3 | $64 |
| Exact Sciences | 2 | $56 |
| Sanofi | 2 | $38 |
| Novartis | 1 | $31 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,777 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $68,712 |
| EliquisApixaban | 26 | $27,340 |
| FarxigaDapagliflozin Propanediol | 12 | $13,631 |
| Atorvastatin Calcium | 166 | $1,798 |
| Trazodone Hcl | 28 | $1,044 |
| Losartan Potassium | 88 | $995 |
| Amlodipine Besylate | 140 | $901 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $842 |
| Pravastatin Sodium | 38 | $839 |
| Mirtazapine | 20 | $782 |
| Metoprolol Succinate | 30 | $761 |
| SynthroidLevothyroxine Sodium | 15 | $732 |
| Gabapentin | 26 | $669 |
| Levothyroxine Sodium | 44 | $628 |
| Lisinopril | 66 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $289 | $68,71242 claims |
| PfizerEliquis | $145 | $27,34026 claims |
| AstraZenecaFarxiga | $372 | $13,63112 claims |
| AbbVieSynthroid | $205 | $73215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.
Other family in Baltimore
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Lisa ScottiBaltimore$35K
- Leah HartBaltimore$32K
- Jinae ArneklevBaltimore$24K
- Valerie OwenBaltimore$12K
- Eldho ChackoBaltimore$12K
- Melonie OwusuBaltimore$10K
- Amanda NevinBaltimore$9K
- Suryamol ChackoBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.